Table 1 Average PSV (cm/s) before and after treatment as stratified by various subgroups

From: Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study

   

Average PSV

 

Group

Patients

Age

Before treatment

After treatment

P value a

A (no vasculop.) PGE1 1–3 times/week (vasculop.)

10

54.6±11.4

42.7±11.1

42.8±11.3

>0.05.

S (no vasculop.) (oral sildenafil) 25 mg at bedtime/night × 1 month

10

55.6±4.6

54.3±12.9

54.9±12.2

>0.05

Av (vasculop.) PGE1 1–3 times/week (vasculop.)

11

56.1±7.5

20.4±5.2

28.3±9.2

<0.05

Sv (vasculop.) (oral sildenafil) 25 mg at bedtime/night × 1 month

12

59.6±6.4

20.5±3.8

25.5±7.2

<0.05

P (vasculop.) (placebo) at bedtime/night for 1 month

12

57.8±6.4

19.6±3.0

21.6±6.3

>0.05

  1. Data were reported as mean±s.d.
  2. aIn vasculogenic impotent men, PSV significantly increased (P<0.05); in some of them, this increase exceeded the normal value of 30 cm/s. The other subgroups, including placebo, remained unchanged.
Back to article page